CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer
Byung Woog Kang, Dong Won Baek, Eunhye Chang, Hye Jin Kim, Su Yeon Park, Jun Seok Park, Gyu Seog Choi, Jin Ho Baek, Jong Gwang Kim

DOI: https://doi.org/10.12701/yujm.2021.01571

Excel Download

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer
Kiley W.J. Loh, Michael Michael, John R. Zalcberg, Michael Jefford
Clinical Colorectal Cancer. 2015;14(3):192-197   Crossref logo
Link1 Link2
ERCC1, Defective Mismatch Repair Status as Predictive Biomarker of Survival for Stage III Colon Cancer Patients Receiving Oxaliplatin Based Adjuvant Chemotherapy
P. Li, G. Chen
Annals of Oncology. 2012;23:ix180   Crossref logo
Link1 Link2
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
P Li, Y J Fang, F Li, Q J Ou, G Chen, G Ma
British Journal of Cancer. 2013;108(6):1238-1244   Crossref logo
Link1 Link2 Link3
Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer
S.R. Verhoeff, F.N. van Erning, V.E.P.P. Lemmens, J.H.W. de Wilt, J.F.M. Pruijt
International Journal of Cancer. 2016;139(1):187-193   Crossref logo
Link1 Link2
Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer
Aalok Kumar, Hagen F. Kennecke, Daniel J. Renouf, Howard J. Lim, Sharlene Gill, Ryan Woods, Caroline Speers, Winson Y. Cheung
Cancer. 2014;121(4):527-534   Crossref logo
Link1 Link2
Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer
Leigh Casadaban, Garth Rauscher, Mebea Aklilu, Dana Villenes, Sally Freels, Ajay V. Maker
Cancer. 2016;122(21):3277-3287   Crossref logo
Link1 Link2
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
Huabin Hu, Zehua Wu, Chao Wang, Yan Huang, Jianwei Zhang, Yue Cai, Xiaoyu Xie, Jianxia Li, Cailu Shen, Weiwei Li, Jiayu Ling, Xuehu Xu, Yanhong Deng
Frontiers in Oncology. 2020;10:   Crossref logo
Link1
A Combined Analysis of Mismatch Repair Status and Thymidylate Synthase Expression in Stage II and III Colon Cancer
Katarina Öhrling, Mia Karlberg, David Edler, Marja Hallström, Peter Ragnhammar
Clinical Colorectal Cancer. 2013;12(2):128-135   Crossref logo
Link1 Link2
Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
Steven Sorscher
Current Problems in Cancer. 2018;42(6):601-604   Crossref logo
Link1 Link2
Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials
Atul Batra, Shiying Kong, Winson Y. Cheung
Clinical Colorectal Cancer. 2020;19(4):e226-e234   Crossref logo
Link1 Link2